The Mesoblast Ltd (ASX: MSB) share price is in focus after the company announced it has reached its patient recruitment target in its pivotal Phase 3 trial for chronic low back pain. This milestone could pave the way for regulatory filing and potential commercial launch of rexlemestrocel-L, Mesoblast’s novel cell therapy.
What did Mesoblast report?
- Pivotal Phase 3 clinical trial (MSB-DR004) for rexlemestrocel-L in chronic low back pain reached full patient enrolment of at least 300 participants
- Trial is placebo-controlled, with 12-month primary endpoint of pain reduction
- Secondary endpoints include improvements in function, quality of life, and opioid cessation
- Top-line results expected mid-calendar year 2027
- Regenerative Medicine Advanced Therapy (RMAT) designation from US FDA, providing eligibility for priority review
What else do investors need to know?
Mesoblast’s Phase 3 trial is evaluating a single intra-discal injection of rexlemestrocel-L, aiming to replicate earlier results that showed clinically meaningful pain reduction and reduced opioid use for up to three years. The company plans to use positive trial outcomes to support a regulatory submission to the US FDA in the second half of 2027, seeking approval for commercialisation.
The company notes that chronic low back pain associated with degenerative disc disease affects more than 7 million Americans. This indication could represent a substantial market opportunity, and Mesoblast’s proprietary cell therapy technology is positioned as a potential disease-modifying, non-opioid alternative.
What did Mesoblast management say?
CEO Silviu Itescu said:
This is a major milestone toward delivering on our corporate goal of bringing to market a non-opioid, disease-modifying therapy for patients suffering from chronic low back pain, a condition with significant unmet medical need.
What’s next for Mesoblast?
Mesoblast expects to deliver top-line Phase 3 results by mid-2027, after the last patient completes follow-up. If successful, the company aims to file a Biologics License Application with the FDA in the third quarter of 2027. RMAT designation may help accelerate review processes.
Meanwhile, Mesoblast continues to advance its broader pipeline in inflammatory diseases and maintains a strong intellectual property portfolio, with over 1,000 patents worldwide. The company’s commercial partnerships in Japan, Europe, and China also provide additional revenue potential.
Mesoblast share price snapshot
Over the past 12 months, Mesoblast shares have risen 17%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 8% over the same period.
The post Mesoblast shares in focus after key Phase 3 milestone for low back pain appeared first on The Motley Fool Australia.
Should you invest $1,000 in Mesoblast right now?
Before you buy Mesoblast shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Mesoblast wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- BSP Financial Group Q1 2026 earnings: Profit and revenue climb as bank continues investment
- Stanmore Resources: Coal output recovers in March quarter
- Zimplats shares: Production dips and costs rise
- Woodside Q1 2026 earnings: Revenue grows, Scarborough and Trion progress
- Liontown shares: Expansion works begin at Kathleen Valley
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.